Researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute have devised a novel way to generate transplantable corneal stem cells that may eventually benefit patients suffering from life-altering forms of blindness.
Iluvien receives marketing authorization in Finland, Luxembourg
The Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg have granted Iluvien marketing authorization for the treatment of vision impairment associated with chronic diabetic macular edema, according to a press release from Alime…
SCORE2 to explore primary, secondary therapies for CRVO
WAILEA, Hawaii — A new study is designed to examine first- and second-line treatments for central retinal vein occlusion, a speaker told colleagues here.Michael S. Ip, MD, discussed design protocols for the Study of Comparative Treatments in Retinal Vein Occlusion 2 (SCORE2) at Retina 2015.
Actavis, Allergan announce SEC declaration, shareholder meetings on pending acquisition
Actavis and Allergan announced that the U.S. Securities and Exchange Commission has declared Actavis’ registration statement on Form S-4 with regard to Actavis’ pending acquisition of Allergan to be effective.The two companies also announced in a press release that they have scheduled special shareholder meetings on March 10 in connection with the pending acquisition.
Speaker shares pearls for better glaucoma management
WAILEA, Hawaii — A speaker presented his pearls for better glaucoma management here at Hawaiian Eye 2015.Physicians should avoid unforced errors in glaucoma, Thomas W. Samuelson, MD, said.
VIDEO: SightLife CEO updates global cornea transplantation achievements, goals
WAILEA, Hawaii – At Hawaiian Eye 2015, Monty Montoya, president and CEO of SightLife, discusses the organizations achievements and future goals for making corneal transplants available worldwide.